
Allchem Lifescience files IPO papers with Sebi; aims to raise Rs 190-cr via fresh issue
IPO comprises fresh issue of equity shares aggregating up to Rs 190 crore and an offer for sale (OFS) of 71.55 lakh equity shares by promoters, according to the draft red herring prospectus (DRHP).
Those selling shares in the OFS are Kantilal Ramanlal Patel and Manisha Bipin Patel.
At present, promoters and promoter group entities hold 100 per cent stake in the company.
In its draft papers filed on Friday, Allchem Lifescience proposes to utilise proceeds from the fresh issue worth Rs 130 crore towards debt payment, while a portion will be used for general corporate purposes as well as to support the business requirements of the company.
Incorporated in 2017, Allchem Lifescience is an Indian manufacturer of active pharmaceutical ingredients (API) intermediates and speciality chemicals.
Live Events
It specialises in the production of key starting materials (KSMs), generic API intermediates and specialty chemicals.
The company is a key player in manufacturing piperazine derivatives, which are critical raw materials for producing APIs like quetiapine, which is used in treating schizophrenia and bipolar disorder.
Over the years, Allchem Lifescience has developed the ability to manufacture 263 products which demonstrates their strong focus on different chemistries in organic chemical compounds.
The company's focus has been to identify potential demand for products, in particular, products that are difficult to source in India or which being import substitutes are not easily available, develop such products and